The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
To read the full story
Related Article
- Ono to Pay 28 Billion Yen to Settle Opdivo Feud with Honjo
November 15, 2021
- Court Pitches Settlement in Opdivo Royalty Row, Response Due Sept. 22
September 13, 2021
- Ono Chief, Honjo Remain Divided over Opdivo Royalty in Direct Face-Off
September 3, 2021
- Ono Chief, Honjo to Face Off in Opdivo Royalty Feud on September 2
August 3, 2021
- Honjo Ups Royalty Claim after Tecentriq Settlement: Opdivo Row
June 14, 2021
- Court’s Settlement Offer on Opdivo Royalty Dispute Fails
April 28, 2021
- Ono, Prof. Honjo Disagree About Validity of Patent Royalty Rate for Opdivo
January 6, 2021
- Ono/BMS Sign Patent License Deal for Tecentriq with Roche
November 10, 2020
- Ono Says Honjo’s 22.6 billion Yen Claim Groundless, No Agreement Reached on 40% Opdivo Fee Proposal
October 27, 2020
- Ono to Fight Prof. Honjo’s Lawsuit over Opdivo Royalties
July 7, 2020
- Nobel Laureate Honjo Sues Ono over Opdivo Royalties, Demands 22.6 Billion Yen
June 22, 2020
- Ono President Confident of Validity of Company’s Argument on Opdivo Royalties
June 19, 2020
- Royalty Feud with Nobel Laureate Takes Center Stage at Ono Shareholder Meeting
June 21, 2019
- Ono Offers Its Account of License Fee Row with Nobel Laureate
May 23, 2019
- I/O Pioneers Win Nobel Prize in Medicine; Honjo Prods Japan Firms to Make More Academic Investment at Home
October 2, 2018
BUSINESS
- Torii, BioCryst Revise Deal for HAE Drug Orladeyo in Japan
December 1, 2023
- Eisai Unit Joins Hands with Thai Authorities on Dementia Drug Access
December 1, 2023
- Mitsubishi Tanabe’s NMOSD Drug Uplizna Now Available in Taiwan
December 1, 2023
- Teijin Earns Japan Rights to 3 Hormone Therapies from Denmark’s Ascendis
November 30, 2023
- Sawai Slapped with Preliminary Injunction for Sprycel Generic over CML Use
November 30, 2023
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…